Press Announcements > FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia

Press Announcements > FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia

FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia 08/17/2017 01:22 PM EDT The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).